Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
HOOK HOOKIPA Pharma Inc
- Stocks
- Healthcare
- NASDAQ: HOOK
Price (delayed)
$1.58
Market cap
$19.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.84
Enterprise value
-$20.52M
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body's immune system.
Highlights
The debt has dropped by 90% year-on-year and by 32% since the previous quarter
HOOK's quick ratio is down by 30% YoY but it is up by 14% from the previous quarter
HOOKIPA Pharma's gross profit has shrunk by 83% YoY and by 79% QoQ
The revenue has shrunk by 83% YoY and by 79% QoQ
Key stats
What are the main financial stats of HOOK
Market
Valuations
Earnings
Shares outstanding
12.19M
Market cap
$19.26M
Enterprise value
-$20.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
2.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.19
Revenue
$9.35M
Gross profit
$9.35M
Operating income
-$80.44M
Net income
-$73.31M
EBIT
-$73.42M
EBITDA
-$70.92M
Free cash flow
-$52.87M
Per share
Balance sheet
Liquidity
EPS
-$5.84
EPS diluted
-$5.84
Free cash flow per share
-$4.38
Book value per share
$2.83
Revenue per share
$0.78
TBVPS
$5.08
Total assets
$61.26M
Total liabilities
$27.18M
Debt
$596,000
Equity
$34.08M
Working capital
$43.45M
Debt to equity
0.02
Current ratio
3.61
Quick ratio
2.93
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
-758.4%
Gross margin
100%
Net margin
-784%
Operating margin
-860.2%
Return on assets
-77.5%
Return on equity
-120.6%
Return on invested capital
-402.2%
Return on capital employed
-164.5%
Return on sales
-785.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOOK stock price
How has the HOOKIPA Pharma stock price performed over time
Intraday
0%
1 week
0%
1 month
17.91%
1 year
-80.23%
YTD
-21.39%
QTD
46.3%
Financial performance
How have HOOKIPA Pharma's revenue and profit performed over time
Revenue
$9.35M
Gross profit
$9.35M
Operating income
-$80.44M
Net income
-$73.31M
Gross margin
100%
Net margin
-784%
HOOKIPA Pharma's gross profit has shrunk by 83% YoY and by 79% QoQ
The revenue has shrunk by 83% YoY and by 79% QoQ
HOOK's net income has dropped by 69% since the previous quarter and by 54% year-on-year
The company's operating income has shrunk by 56% QoQ and by 26% YoY
Price vs fundamentals
How does HOOK's price correlate with its fundamentals
Growth
What is HOOKIPA Pharma's growth rate over time
Valuation
What is HOOKIPA Pharma stock price valuation
P/E
N/A
P/B
0.56
P/S
2.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.19
The EPS has plunged by 68% from the previous quarter and by 17% YoY
The company's equity has shrunk by 67% YoY and by 33% QoQ
The P/B is 49% below the 5-year quarterly average of 1.1 and 7% below the last 4 quarters average of 0.6
The price to sales (P/S) is 104% higher than the last 4 quarters average of 1.0 but 70% lower than the 5-year quarterly average of 6.8
The revenue has shrunk by 83% YoY and by 79% QoQ
Efficiency
How efficient is HOOKIPA Pharma business performance
The ROA has plunged by 170% YoY and by 106% from the previous quarter
HOOKIPA Pharma's return on equity has shrunk by 155% YoY and by 117% QoQ
The company's return on invested capital has shrunk by 126% QoQ and by 53% YoY
Dividends
What is HOOK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOOK.
Financial health
How did HOOKIPA Pharma financials performed over time
The total assets is 125% more than the total liabilities
The total assets has plunged by 58% YoY and by 26% from the previous quarter
The total liabilities has declined by 34% year-on-year and by 13% since the previous quarter
The debt is 98% smaller than the equity
The debt has dropped by 90% year-on-year and by 32% since the previous quarter
The company's equity has shrunk by 67% YoY and by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.